Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • Gonorrhoea strains ...

    Gonorrhoea strains becoming more susceptible to available treatment options

    Written by Anjali Nimesh Nimesh Published On 2017-09-15T10:47:58+05:30  |  Updated On 15 Sept 2017 10:47 AM IST
    Gonorrhoea strains  becoming more susceptible to available treatment options

    According to test results from the annual European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), resistance levels to the main antimicrobials used for treatment of gonorrhoea infection have seen an encouraging decrease since 2010. However, resistance to one antibiotic agent which is part of the suggested dual therapy of gonorrhoea remains high and threatens the effectiveness of this regimen.


    Every year, countries of the European Union and European Economic Area (EU/EEA) participate in Euro-GASP to test susceptibility of Neisseria gonorrhoeae to the antibiotics commonly used for gonorrhoea treatment. In 2015, 24 EU/EEA countries collected and tested more than 2 000 gonococcal isolates that showed stable proportions of resistance against the antimicrobials cefixime, ciprofloxacin and azithromycin compared to 2014 and only one isolate resistant to ceftriaxone.


    Cefixime resistance decreased slightly to 1.7% in 2015 in comparison to the year before (2%). Ciprofloxacin resistance, although still very high, has decreased from 53% in 2013 to 49% in 2015 and the level of azithromycin resistance went down from 8% in 2014 (169 out of 2 147 isolates) to 7% in 2015. However, five isolates displayed high-level resistance to azithromycin, compared with only one in 2014. Only one isolate displayed resistance to ceftriaxone in 2015, compared to five in 2014 and seven in 2013.


    The continuing increase in cephalosporin susceptibility is good news considering that these are among the last remaining options for treatment of gonorrhea infection. Despite this, the level of azithromycin resistance and the rise in the number of isolates with high-level resistance to azithromycin are of major concern and threaten the effectiveness of the dual antimicrobial treatment regimen.


    The ECDC report Gonococcal antimicrobial susceptibility surveillance in Europe 2015 shows that information about which antimicrobials were used to treat gonorrhoea infection were available for 36.5% of patients (779 of 2134 isolates). 58% of these received the recommended treatment of ceftriaxone and azithromycin, although the dosages were not available. Overall, 87% were administered ceftriaxone with or without azithromycin, so the use of the recommended and more appropriate ceftriaxone may have contributed to this increase in cephalosporin susceptibility. More heterosexual males received the recommended treatment (67%) than females (57%) and men who have sex with men (52%).


    Euro-GASP monitors emerging resistance trends A


    The control of gonorrhoea depends on effective antimicrobial treatment, even a small increase in drug resistance has a relevant impact due to the risk of treatment failure.


    Since the European treatment guidelines for gonorrhoea recommend use of two antimicrobials (ceftriaxone or cefixime in combination with azithromycin), the surveillance of antimicrobial susceptibility of these agents - which is currently undertaken by ECDC's Euro-GASP - is vital to guide clinical services to ensure that patients are successfully treated and the risk of complications are avoided.


    With more than 66 000 reported cases in 2014, and many more infections occurring but not reported, gonorrhoea is the second most frequently recorded sexually transmitted infection in Europe after chlamydia.


    ECDC launched a regional response plan to control multidrug-resistant gonorrhoea to minimise the threat of drug-resistant gonorrhoea in Europe. This plan argues that countries need to ensure they have the minimum capacity for culture and susceptibility testing. They must also have strategies for rapid identification and reporting of failures to treatment with currently recommended antimicrobials.


    At the same time, antimicrobial resistance surveillance and awareness of this problem should be stepped up so that measures can be taken to ensure that options for successful treatment of gonorrhoea remain available in the EU.

    cefiximeceftriaxonecephalosporinCiprofloxacin resistancedrug resistancegonorrhoeaNeisseria gonorrhoeaesexually transmitted infection
    Source : EurekaAlert

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Anjali Nimesh Nimesh
    Anjali Nimesh Nimesh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok